OVERVIEW

18th Annual Winter Lung Cancer Conference® is organized by Physicians' Education Resource, LLC (PER).

Event Date: Friday, February 5, 2021 – Sunday, February 7, 2021

Overview:
The upcoming 18th Annual Winter Lung Cancer Conference®, a first-class continuing medical education event for the treatment of patients with lung cancer. Based on the traditional format of expert overviews with dynamic Medical Crossfire® exchanges, this meeting will present you with the most cutting-edge research and practical knowledge for the care of your patients. You will also have a preview of distinct agents and techniques that will inform the future of lung cancer treatment.

This program, led by world-class thoracic oncologists, offers you the chance to learn from and interact with international experts in several therapeutic areas, including immunotherapy, targeted agents, and multidisciplinary approaches. Throughout the program, question-and-answer sessions will enable you to consult with faculty and your community-based peers. Come to learn, but also to share your personal experiences and best practices in lung cancer management.

By participating in this exciting program, you will have the opportunity to learn state-of-the-art care, including:
• Integration and optimization of molecular testing throughout the continuum of disease
• Leveraging the growing therapeutic armamentarium for oncogene-driven non–small cell lung cancer (NSCLC)
• Navigating options for first-line immunotherapy-based regimens in metastatic NSCLC
• Application of consolidation immunotherapy in locally advanced NSCLC
• Current approaches with surgery and radiation oncology in patients with thoracic malignancies

Benefits of Attending:
• Learn the latest about new and emerging treatment options for patients with thoracic malignancies
• Hear expert perspectives on the clinical application of recent data, and on areas of clinical uncertainty and controversy
• Network with your peers and world-renowned thought leaders
• Improve the patient-centered care you provide to your patients

Objectives:
At the conclusion of this activity, you should be better prepared to:
• Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC
• Evaluate emerging approaches for patient selection for immunotherapy and targeted agents
• Assess treatment strategies for early-stage and locally advanced lung cancer
• Describe the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
• Incorporate immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
• Discuss approaches to mitigate and manage treatment-related adverse events in patients with lung cancer